Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Market Snippet by Disease Type
3.2. Market Snippet by Drug Class
3.3. Market Snippet by End users
3.4. Market Snippet by Region
4. Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Number of People Suffering From Conjunctivitis
4.1.1.2. Easy Availability of the Treatment
4.1.2. Restraints
4.1.2.1. Availability of Alternative Treatments Such as Home Remedies
4.2. Impact Analysis
4.3. Opportunity
5. Industry Analysis
5.1. Porter’s Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Regulatory Analysis
5.4. Pricing Analysis
5.5. Product Analysis
5.6. COVID-19 Impact Analysis
6. By Disease Type
6.1. Introduction
6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
6.3. Market Attractiveness Index, By Disease Type
6.3.1. Allergic Conjunctivitis *
6.3.1.1. Introduction
6.3.1.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2019-2027
6.3.2. Bacterial Conjunctivitis
6.3.3. Viral Conjunctivitis
7. By Drug Class
7.1. Introduction
7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
7.3. Market Attractiveness Index, By Disease
7.3.1. Antibiotics
7.3.1.1. Introduction
7.3.1.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2019-2027
7.3.2. Ophthalmic Steroids
7.3.3. Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
7.3.4. Antihistamines
7.3.5. Others
8. By End-users
8.1. Introduction
8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users Market Attractiveness Index, By End-users
8.2.1. Hospitals
8.2.2. Introduction
8.2.3. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2019-2027
8.3. Specialty Clinics
8.4. Others
9. By Region
9.1. Introduction
9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
9.3. Market Attractiveness Index, By Region
9.4. North America
9.4.1. Introduction
9.4.2. Key Region-Specific Dynamics
9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.4.6.1. U.S.
9.4.6.2. Canada
9.4.6.3. Mexico
9.5. Europe
9.5.1. Introduction
9.5.2. Key Region-Specific Dynamics
9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.5.6.1. Germany
9.5.6.2. U.K.
9.5.6.3. France
9.5.6.4. Rest of Europe
9.6. South America
9.6.1. Introduction
9.6.2. Key Region-Specific Dynamics
9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
9.6.5. . Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
9.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.6.6.1. Brazil
9.6.6.2. Argentina
9.6.6.3. Rest of South America
9.7. Asia Pacific
9.7.1. Introduction
9.7.2. Key Region-Specific Dynamics
9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%),End-users
9.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
9.7.6.1. China
9.7.6.2. India
9.7.6.3. Japan
9.7.6.4. Australia
9.7.6.5. Rest of Asia Pacific
9.8. Middle East and Africa
9.8.1. Introduction
9.8.2. Key Region-Specific Dynamics
9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
10. Competitive Landscape
10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis
11. Company Profiles
11.1. Boehringer Ingelheim GmbH *
11.1.1. Company Overview
11.1.2. Product Portfolio and Description
11.1.3. Key Developments
11.1.4. Financial Overview
11.2. Allergan Inc.
11.3. Sanofi-Aventis
11.4. Novartis AG
11.5. Bausch & Lomb Inc.
11.6. CIBA Vision Ophthalmics
11.7. Pfizer Inc.
11.8. Merck & Co., Inc.
11.9. Santen Pharmaceuticals Co. Ltd.
11.10. Akron Incorporated(*List is not exhaustive)
12. Premium Insights
13. DataM Intelligence
13.1. Appendix
13.2. About Us and Services
13.3. Contact Us